Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$271.71 USD

271.71
830,236

-0.89 (-0.33%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $271.82 +0.11 (0.04%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Masimo (MASI) Gets FDA Nod for RRp Monitoring Technology

by Zacks Equity Research

The FDA clearance of this monitoring system is expected to strengthen Masimo's (MASI) portfolio of pulse oximetry technologies.

Zacks Equity Research

Here's Why You Should Add Hologic Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on its strong segmental performance in Q1.

Zacks Equity Research

Neogen Expands With Cell Biosciences' Food Safety Asset Buyout

by Zacks Equity Research

Neogen (NEOG) expands presence in Australia with asset buyout from Cell BioSciences.

Zacks Equity Research

CryoLife Wins CE Mark, Boosts Mechanical Valve Foothold in EU

by Zacks Equity Research

CryoLife's (CRY) On-X AAP completes the company's On-Xs heart valve portfolio.

Zacks Equity Research

Here's Why You Should Add STERIS (STE) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about STERIS (STE) on its strong segmental performance in Q3.

Zacks Equity Research

Medtronic Demonstrates All-Line Growth Despite Cost Concerns

by Zacks Equity Research

Major business lines of Medtronic (MDT) register stellar growth across all customer groups and geographies in Q3.

Zacks Equity Research

Here's Why You Should Buy Edwards Lifesciences Stock Now

by Zacks Equity Research

Investor confidence is high in Edwards Lifesciences (EW) stock, courtesy of solid prospects.

Zacks Equity Research

Luminex Files for FDA 510(k) Clearance of RSP Flex Assay

by Zacks Equity Research

Once the regulatory clearance comes through, Luminex's (LMNX) Assay portfolio is expected to receive a major boost.

Zacks Equity Research

ResMed (RMD) Down 3.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Patterson Companies (PDCO) Catches Eye: Stock Jumps 5.9%

by Zacks Equity Research

Patterson Companies (PDCO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zacks Equity Research

Syneos Health Grows on New Alliances Amid Regulatory Upheavals

by Zacks Equity Research

Syneos Health's (SYNH) new partnerships with AiCure and Indegene Omnipresence seem strategic at the moment.

    Zacks Equity Research

    Here's Why You Should Hold Syneos Health in Your Portfolio Now

    by Zacks Equity Research

    Syneos Health (SYNH) enjoys high investor confidence on solid prospects.

      Zacks Equity Research

      Integra Launches AmnioExcel Placental Allograft Membrane

      by Zacks Equity Research

      The launch of this product is expected to boost Integra's (IART) OTT segment.

      Zacks Equity Research

      Orthofix Supports FDA Class III Label Continuation for BGS

      by Zacks Equity Research

      Orthofix (OFIX) pledges support for the continuation of the FDA's Class III status of BGS devices.

      Trina Mukherjee headshot

      Medical Products Industry Outlook: Growth Prospects Bright

      by Trina Mukherjee

      Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.

      Zacks Equity Research

      ResMed (RMD): Strong Industry, Solid Earnings Estimate Revisions

      by Zacks Equity Research

      ResMed (RMD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

      Zacks Equity Research

      QIAGEN Ships Test Kits to China for Detecting Coronavirus

      by Zacks Equity Research

      QIAGEN (QGEN) expands the molecular testing portfolio by shipping QIAstat-Dx Respiratory 2019-nCoV Panel to China for faster detection of coronavirus SARS-CoV-2.

      Zacks Equity Research

      STERIS (STE) Stock Hits New 52-Week High: What's Driving it?

      by Zacks Equity Research

      STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with several tuck-in acquisitions.

      Zacks Equity Research

      Insulet (PODD) Q4 Earnings Lag Estimates, Revenues Beat

      by Zacks Equity Research

      Insulet's (PODD) fourth-quarter 2019 results reflect strong segmental performances.

      Zacks Equity Research

      Intersect ENT (XENT) Reports Narrower-Than-Expected Q4 Loss

      by Zacks Equity Research

      Intersect ENT (XENT) exhibits a dismal performance in the fourth quarter of 2019.

      Zacks Equity Research

      Tandem Diabetes (TNDM) Q4 Earnings Beat Estimates, Margins Up

      by Zacks Equity Research

      Tandem Diabetes (TNDM) once again registers strong domestic pump shipment in Q4.

      Zacks Equity Research

      Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

      by Zacks Equity Research

      Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international performance in Q4.

      Zacks Equity Research

      Teleflex (TFX) Earnings and Revenues Beat Estimates in Q4

      by Zacks Equity Research

      Teleflex's (TFX) fourth-quarter 2019 results reflect strong segmental performances.

      Zacks Equity Research

      Zacks.com featured highlights include: Microsoft, Ruth???s Hospitality, ResMed, Ross Stores and Maxim Integrated Products

      by Zacks Equity Research

      Zacks.com featured highlights include: Microsoft, Ruth???s Hospitality, ResMed, Ross Stores and Maxim Integrated Products

      Zacks Equity Research

      Integra (IART) Q4 Earnings Surpass Estimates, Margins Up

      by Zacks Equity Research

      Integra's (IART) fourth-quarter 2019 results reflect strong segmental performances.